Kyrgyzstan Medical Device Registration Certificate Holder Changes: Dossier Amendment Rules and 2028 Deadline

1. Key takeaways

The identity of the certificate holder on a Kyrgyzstan registration certificate overlaps with two other concepts, the applicant and the authorized representative. The applicant is the party that submits the application; the authorized representative is the resident entity that bears responsibility; the holder is the rights-holding entity named on the certificate. In most foreign manufacturer projects all three roles fall on the same authorized representative, but this is an operational choice, not a legal consolidation. Whichever entity the roles fall on, any change to entity information requires an amendment of the registration dossier, without exception.

2. Legal basis

1. Cabinet Resolution No. 513, August 27, 2024, Annex 1, Article 2: the applicant is the party submitting the registration and change applications; the authorized representative is the resident entity bearing responsibility.
2. Annex 1, Article 1, to Cabinet Resolution No. 513: the procedure governs amendments of the registration dossier.
3. Public forms of the competent authority: Annex 2 (change application form) and Annex 4 (registration certificate format).
4. Law No. 216, Article 14: the obligation to report changes to device data and information rests with the manufacturer or its authorized representative.
5. Law No. 216, Article 15: registration certificates are issued for an unlimited period; suspension and revocation circumstances.

3. Expert insights

Insight 1: the separation of the three concepts is design space for risk control.

The applicant, the authorized representative, and the holder are three distinct legal identities. In most projects the authorized representative takes all three at once, which is efficient but concentrates risk. A company may also choose to have the manufacturer itself act as the holder, with the authorized representative exercising procedural rights only. Under that arrangement the attribution of rights on the certificate is clearer, but it requires the manufacturer to have real capability to exercise rights in Kyrgyzstan, including an electronic system account, document signing, and official communication. Both arrangements involve trade-offs; they should be settled expressly in the agreement rather than left to defaults.

Insight 2: changes to entity information are a high-frequency trigger in the change procedure.

Entity information that triggers a change includes a change of manufacturer name, a change of manufacturer address, covering both the registered and the actual address, a change of manufacturing site, a change of authorized representative, and a change of corporate form, such as through merger or demerger. Among these, a change of manufacturer address is the most easily overlooked. Many companies assume an address change does not affect the product, yet in the registration dossier the address is one of the core elements identifying the manufacturer.

Insight 3: the unlimited validity of the certificate magnifies the long-term pressure of entity data maintenance.

As discussed in Part 08 of this series, registration certificates are issued for an unlimited period and carry no expiry date. This means the duty to maintain entity information is also unlimited. There is no opportunity to wait and update everything at the next renewal. If a company name or address changes, an amendment must be proactively filed; otherwise the dossier record stays inaccurate, and inaccuracy is precisely the source of suspension and revocation risk.

Insight 4: entity changes in the late transition period trigger pathway migration.

For certificates obtained under the national track, dossier changes can only be handled under national rules until December 31, 2028. If a change of authorized representative or of manufacturer entity occurs after 2029, it can only be redone under Union rules. This is the structural tension between an indefinitely valid certificate and a time-limited change window, and it is why, in Part 11 of this series, we recommend settling entity arrangements within the transition period.

Insight 5: the change application form in Annex 2 is the entry point of the change procedure.

The competent authority publishes a dedicated change application form. The change procedure shares the same electronic system as the initial registration, and also shares the same consistency requirements. The new information stated in a change application must likewise be supported by corroborating documents; for example, a name change requires a corporate registry change certificate, completed with notarization, legalization, and translation.

4. Practical recommendations

First, settle the holder arrangement in the agreement. We recommend expressly agreeing on who is named as the holder on the registration certificate, the rights and obligations of each party under the certificate, and the cooperation duties when a change arises. This avoids later disputes caused by default arrangements.

Second, build a trigger list for entity information changes. We recommend listing in the internal quality system documents all circumstances that trigger a change: name, address, manufacturing site, authorized representative, and corporate form. Any single change should initiate a change assessment.

Third, bring change handling into M&A and restructuring due diligence. If a group-level restructuring, demerger, or equity transfer occurs, we recommend assessing whether it affects the entity information in the registration dossier, and allocating responsibility and cost for the change in the transaction documents.

Fourth, complete entity arrangements before the end of the transition period. We recommend completing all known entity information changes before December 31, 2028, including the long-term arrangement for the authorized representative.

Fifth, apply the consistency check to change applications as well. We recommend that change applications reuse the standard wording table and consistency review process of the initial registration, to avoid corrections caused by mixing old and new information.

5. Verification checklist

• □ The holder arrangement on the registration certificate and the rights and obligations of each party have been settled in the agreement;
• □ A trigger list for entity information changes has been established: name, address, manufacturing site, authorized representative, corporate form;
• □ Group-level events such as M&A and restructuring have been included in the dossier impact assessment;
• □ Known entity information changes are scheduled for completion before 2028-12-31;
• □ Change applications use the current published Annex 2 form of the competent authority;
• □ Change applications also undergo the consistency check and are accompanied by complete corroborating documents, including notarization, legalization, and translation.

Regulatory information verified as of October 29, 2026.

Our services cover pre-market pathway selection and feasibility assessment, registration dossier preparation and submission, authorized representative arrangements, local testing and clinical trial organization, manufacturing site inspection coordination, quality management system compliance coaching, post-market surveillance and vigilance system setup, import and distribution compliance, state fee estimation, and project budget management.

The GRZAN regulatory team consists of professionals with many years of hands-on experience in Eurasian Economic Union registrations. It maintains a stable local cooperation network in Bishkek, Almaty, Tashkent, Moscow, and other cities, and works in Chinese, Russian, and English. For the key issues that foreign manufacturers commonly face in CIS markets, including authorized representative arrangements, the notarization and legalization chain for powers of attorney, localization of technical documentation, and inspection response, GRZAN provides executable solutions.

We hold to one principle: every regulatory conclusion we publish must be traceable to verifiable official sources. Any figure or timeline that cannot be verified is always labeled as a practical estimate, and experience values are never presented as legal grounds.

GRZAN provides registration and compliance support in Kyrgyzstan for medical device manufacturers, importers, and authorized representatives. For project consultation on market access in Kyrgyzstan or the Eurasian Economic Union, please contact us at info@grzanglobal.com.

GRZAN | Global Medical Device Regulatory Registration and Compliance Services